Jump to content

David T. Curiel

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Wozal (talk | contribs) at 16:02, 18 December 2023 (ce.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

David T. Curiel
Born1956 (age 67–68)
Douglasville, Georgia, USA
Academic background
EducationBSc, Chemistry, 1978, West Georgia College
MD, 1982, Emory University School of Medicine
PhD, Virology, 2002, University of Groningen
ThesisGenetic capsid modification for adenovirus retargeting (2002)
Academic work
InstitutionsWashington University in St. Louis
University of Alabama at Birmingham
University of North Carolina at Chapel Hill

David Terry Curiel (born 1956) is an American cancer biologist. He is a professor of Radiation Oncology at Washington University School of Medicine and Director of the Biologic Therapeutics Center. In 1995, Curiel led a research team who were the first to develop a vaccine based on messenger RNA. Although they published proof of concept, he could not continue testing due to a lack of funding. In 2021, Curiel developed a vaccine that targets the SARS-CoV-2 virus through the nose.

Early life and education

Curiel was born in 1956[1] in the Douglasville, Georgia area.[2] His father, a general practitioner,[2] immigrated to the United States from the Dominican Republic. Curiel is of Jewish descent.[3] Following high school, Curiel remained in his home state for his Bachelor of Science degree at West Georgia College and medical degree at the Emory University School of Medicine. Upon receiving his medical degree, Curiel completed his internship and residency at Emory in 1985 and his fellowships in pulmonary medicine and biotechnology at the National Institutes of Health in 1990.[4] He enrolled at the University of Groningen in the Netherlands for his PhD.[5]

Career

Following his fellowships, Curiel became an assistant professor of medicine at the University of North Carolina at Chapel Hill (UNC).[6] In this role, he began working on gene transfer techniques for the treatment of cystic fibrosis. In 1992, he began combining two different gene therapy approaches into a virus using Adenovirus. Healthy genes are transferred to defective cells on the outer coat of inactivated adenoviruses which in turn enter the cell nuclei where defective genes lie.[7][8] His research efforts earned him the 1992 James W Woods Junior Faculty Award from UNC.[6] Following this, Curiel was appointed Director of the University of Alabama at Birmingham's (UAB) Gene Therapy Program in 1993.[2] While serving in this role, Curiel led a research team who were the first to develop a vaccine based on messenger RNA. Although they published proof of concept, he could not continue testing due to a lack of funding and public interest.[9] Curiel also served as the principal investigator (PI) of a team researching how to develop unique methods of delivering genes to specific targets.[10] His efforts in gene therapy earned him the funding to study a system to define tumor cell signatures.[11] In January 2000, Curiel was appointed Director of the Division of Human Gene Therapy at UAB's Heersink School of Medicine.[2]

As Director of the Division of Human Gene Therapy, Curiel oversaw a consortium of scientists who modified an adenovirus that reproduces inside tumor cells in order to eradicate them called Delta-24-RGD.[12] This was thought to be the first treatment for malignant glioma. While testing the Delta-24-RGD treatment with scientists at the MD Anderson Cancer Center, their research teams found that the treatment would completely eradicate brain tumors in mice, while leaving healthy brain tissue alone.[13] He also founded VectorLogics, Inc. in order to develop products to treat ovarian cancer.[14] In 2004, Curiel was a finalist for the Director position at the University of Arizona's Institute for Biomedical Science and Biotechnology.[5] However, he chose to remain at UAB until 2011 when he became Director of Washington University in St. Louis' (WUSTL) Biologic Therapeutics Center.[15] During his final years at UAB, Scientific American magazine deemed Curiel's 2003 co-authored paper on virotherapy as "one of 10 groundbreaking stories of the past 10 years."[16][17]

Upon joining the faculty at WUSTL in 2011, Curiel was appointed a professor of radiation oncology with tenure.[18] He also merged his company VectorLogics, Inc. with DNAtrix, a biotechnology company developing targeted adenovirus-based oncolytic virus products for brain cancer.[14] In 2012, Curiel collaborated with scientist Mike Mathis from LSU to test the adenovirus on colon cancer in mice.[19] These experiments resulted in the discovery that the adenovirus could target tumor blood vessels in mice without affecting healthy tissues.[20] His use of viral vector technology to optimize the immune system's response to vaccines earned him one of the 2015 Bear Cub Challenge award from the Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship.[21] Due to the 2015–16 Zika virus epidemic, Curiel and Precision Virologics commercialized an adenovirus vaccine to prevent the disease and others.[22] In 2019, he received funding from the National Center for Advancing Translational Sciences to support his research into discovering new therapeutics for genetic diseases.[23] This eventually developed into a new approach to facilitate the "CAR-T" immunotherapy that makes it cheaper and more patient-accessible.[24]

During the COVID-19 pandemic, Curiel harnessed gene therapy and viral vectors to develop therapeutics and vaccines to combat the novel coronavirus.[25] Early in the pandemic, Curiel and Michael S. Diamond re-engineered Adenovirus to carry the Sars-Covid2 spike gene in order to protect against infection and sterilize the upper airways. Their single-dose, nasal vaccine was proven successful in mice and nonhuman primates which led them to begin trials in India with Bharat Biotech.[26][27] Curiel was later named a senior member of the National Academy of Inventors for his gene-therapy research.[28] In late January 2023, the nasal vaccine received approval from India's Ministry of Health and Family Welfare and Science and Technology Minister Jitendra Singh to be added to the primary 2-dose schedule.[29]

References

  1. ^ "Curiel, David Terry, 1956-". VIAF. Archived from the original on February 5, 2023. Retrieved January 13, 2023.
  2. ^ a b c d McIntosh, Charlotte (October 2, 2000). "Gene therapy making strides". Birmingham Post-Herald. Archived from the original on February 5, 2023. Retrieved January 13, 2023 – via newspapers.com.
  3. ^ Berger, Eric (March 9, 2021). "WU researcher pioneered process used in COVID vaccines". St. Louis Jewish Light. Archived from the original on December 23, 2022. Retrieved January 13, 2023.
  4. ^ "David T. Curiel, MD, PhD". Washington University in St. Louis. 19 October 2016. Archived from the original on January 9, 2023. Retrieved January 13, 2023.
  5. ^ a b Wichner, David (March 4, 2004). "UA institute has narrowed director candidates to four". Arizona Daily Star. Archived from the original on February 5, 2023. Retrieved February 1, 2023 – via newspapers.com.
  6. ^ a b Airington, Tracy (September 2, 1992). "Junior medical faculty chosen for Wood award". The Chapel Hill Herald. Archived from the original on February 5, 2023. Retrieved January 13, 2023 – via newspapers.com.
  7. ^ Blythe, Anne (April 9, 1992). "Gene technique may be breakthrough". The Chapel Hill News. Archived from the original on February 5, 2023. Retrieved January 13, 2023 – via newspapers.com.
  8. ^ Kanigel, Rachele (April 9, 1992). "UNC-CH gene findings promising". The News and Observer. Archived from the original on February 5, 2023. Retrieved January 13, 2023 – via newspapers.com.
  9. ^ Pou, Toni (3 July 2021). "RNA vaccines: A story of scientific tenacity". Diari ARA. Archived from the original on July 27, 2021. Retrieved February 1, 2023.
  10. ^ "$13 million breast cancer grant establishes UAB among Nation's leaders". Abbeville Herald. October 5, 2000. Archived from the original on February 5, 2023. Retrieved February 1, 2023 – via newspapers.com.
  11. ^ "First 'Unconventional Innovations Program' NCI Grants Awarded". Oncology NEWS International Vol 8 No 12. Cancer Network. December 1, 1999. Archived from the original on October 4, 2022. Retrieved February 1, 2023.
  12. ^ "Better Gene Therapy". Newswire. February 23, 2002. Archived from the original on February 5, 2023. Retrieved February 1, 2023.
  13. ^ "Smart Virus Eliminates Brain Cancer In Animal Experiments". Science Daily. May 7, 2003. Archived from the original on April 18, 2021. Retrieved February 1, 2023.
  14. ^ a b "DNAtrix and VectorLogics, Inc. Complete Merger Transaction". BioSpace. October 23, 2012. Archived from the original on February 5, 2023. Retrieved February 1, 2023.
  15. ^ Baugher, David (September 20, 2011). "Bench to bed: Washington University is carrying research from the lab to practice". St. Louis NPR. Archived from the original on February 5, 2023. Retrieved February 1, 2023.
  16. ^ "Virotherapy in spotlight again, in use at bedside". University of Alabama at Birmingham. September 11, 2008. Retrieved February 1, 2023.
  17. ^ "Tumor-Busting Viruses". Scientific American. July 1, 2008. Archived from the original on February 6, 2016. Retrieved February 1, 2023.
  18. ^ "Trustees grant faculty promotions, tenure". Washington University in St. Louis. April 5, 2011. Archived from the original on August 9, 2022. Retrieved February 1, 2023.
  19. ^ Brumble, Melody (February 23, 2012). "Curing cancer". The Times. Archived from the original on February 5, 2023. Retrieved February 3, 2023 – via newspapers.com.
  20. ^ "Gene therapy method targets tumor blood vessels". Science Daily. December 23, 2013. Archived from the original on November 16, 2018. Retrieved February 3, 2023.
  21. ^ Evangelou Strait, Julia (December 8, 2015). "Bear Cub Challenge awardees announced". Archived from the original on August 16, 2022. Retrieved February 3, 2023.
  22. ^ Feldt, Brian (March 31, 2017). "St. Louis startup attacking Zika raises $500,000 from Japanese firm". St. Louis Business Journal. Archived from the original on April 2, 2017. Retrieved February 3, 2023.
  23. ^ "$2.2 million supports research into genome editing". Washington University in St. Louis. December 3, 2019. Archived from the original on February 5, 2023. Retrieved February 3, 2023.
  24. ^ "SIX FACULTY PROJECTS LEAP TOWARD COMMERCIALIZATION". Washington University in St. Louis. May 11, 2020. Archived from the original on February 5, 2023. Retrieved February 3, 2023.
  25. ^ "St. Louis scientist developing 'no shot' COVID-19 vaccine". NewsNation. January 23, 2021. Archived from the original on September 23, 2021. Retrieved January 13, 2023.
  26. ^ "Michael S. Diamond, MD, PhD creates world's first nasal COVID-19 vaccine, approved in India". Washington University in St. Louis. September 9, 2022. Archived from the original on January 13, 2023. Retrieved January 13, 2023.
  27. ^ Nicklaus, David (September 23, 2020). "St. Louis startup licenses 'underdog' COVID-19 vaccine from Washington University". St. Louis Post-Dispatch. Archived from the original on September 24, 2020. Retrieved February 3, 2023.
  28. ^ "Curiel named to National Academy of Inventors". University of Washington at St. Louis. February 16, 2022. Archived from the original on December 6, 2022. Retrieved January 13, 2023.
  29. ^ Das, Basudha (January 26, 2023). "India gets its first intranasal vaccine for COVID for Rs 800 per dose". businesstoday.in. Archived from the original on January 28, 2023. Retrieved February 3, 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=David_T._Curiel&oldid=1190561588"